In the ischemia/reperfusion-induced fibrosis C57BL/6J mouse model, transcriptomic and metabolomic analyses showed that dapagliflozin treatment mitigated accumulation of tricarboxylic acid (TCA) circulating metabolites and up-regulation of inflammation in fibrotic renal cortical tissue
Liver and cardiovascular markers: Cagrilintide is also studied for impacts on liver fat, cardiovascular risk markers, and systemic metabolic signaling, including lipid profiles
Researchers became understandably interested in BPC-157 after observing its remarkable reparative impact on the stomach lining and other tissues in animals
Through them, we gained an invaluable understanding of real-world experiences from a clinical perspective
Users describe warmth spreading through the chest, face, and extremities within 15-30 minutes after injection
What the Research Does NOT Yet Support - There are currently no published randomised controlled trials (RCTs) in humans for BPC-157 - Human pharmacokinetic data (how it is absorbed, distributed, metabolised, and excreted) is limited - Optimal dosing, route of administration, and treatment duration have not been established clinically - Long-term safety data in humans is absent - Regulatory approval from the TGA, FDA, or EMA has not been granted for any therapeutic indication TB-500: Evidence Overview What the Research Supports TB-500 / Thymosin Beta-4 has somewhat more human-facing research, though still predominantly preclinical: Phase I and II clinical trials have investigated Thymosin Beta-4 (the native peptide) in cardiac repair following myocardial infarction, with promising safety profiles Wound healing applications have been explored in clinical settings, particularly for chronic non-healing wounds and dry eye disease Robust animal evidence supports its role in reducing inflammation, supporting angiogenesis, and promoting tissue regeneration The native peptide (T4) has demonstrated cardioprotective effects in animal models of heart failure and ischaemia What the Research Does NOT Yet Support TB-500 is a synthetic fragment of T4 it is not identical to the native peptide, and extrapolating human clinical data from T4 studies directly to TB-500 may not be valid No approved therapeutic indications exist for TB-500 specifically Comparative efficacy versus established treatments has not been studied The long-term effects of exogenous peptide administration on endogenous thymosin beta-4 regulation are unknown Potential Benefits: A Summary Based on the available (predominantly preclinical) literature, the following potential benefits have been identified: Risks & Safety Considerations Known & Reported Side Effects Because large-scale human trials are lacking, our understanding of the side effect profile is limited
